Brokerages Set STAAR Surgical (NASDAQ:STAA) Price Target at $42.83

Shares of STAAR Surgical (NASDAQ:STAAGet Free Report) have earned an average rating of “Hold” from the nine analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $42.83.

Several equities analysts recently weighed in on STAA shares. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Tuesday. Finally, Canaccord Genuity Group decreased their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th.

Read Our Latest Research Report on STAAR Surgical

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 23,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were acquired at an average cost of $24.33 per share, with a total value of $559,590.00. Following the completion of the acquisition, the insider now directly owns 10,848,631 shares in the company, valued at approximately $263,947,192.23. This trade represents a 0.21 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of STAA. Arcadia Investment Management Corp MI purchased a new stake in STAAR Surgical during the 3rd quarter worth approximately $37,000. Quarry LP acquired a new stake in shares of STAAR Surgical in the third quarter worth approximately $50,000. Quest Partners LLC purchased a new stake in shares of STAAR Surgical during the third quarter worth approximately $128,000. Canada Pension Plan Investment Board acquired a new position in STAAR Surgical in the 2nd quarter valued at $129,000. Finally, Van ECK Associates Corp lifted its holdings in STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

Shares of STAA stock opened at $23.00 on Monday. STAAR Surgical has a fifty-two week low of $22.20 and a fifty-two week high of $52.68. The firm has a market capitalization of $1.13 billion, a PE ratio of 52.27 and a beta of 0.63. The stock’s 50-day simple moving average is $26.31 and its 200-day simple moving average is $32.87.

STAAR Surgical Company Profile

(Get Free Report

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

Featured Stories

Analyst Recommendations for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.